Transforming 
drug discovery with generative AI

Evolving at the intersection of AI and drug discovery

Our team brings together deep expertise across machine learning, medicinal chemistry, and computational chemistry, applied to the challenges of small molecule drug discovery. Our AI scientists have been trained and conducted research at some of the world’s leading academic and industrial laboratories, including MIT, Caltech, Berkeley, Google, Microsoft Research, and D-Wave Quantum, and combine cutting-edge expertise in generative modeling with strong foundations in applied mathematics and computational science. Alongside experienced medicinal and computational chemists with first-hand pharmaceutical R&D experience, Variational AI’s multidisciplinary team ensures that Enki is grounded in rigorous science and built as a practical solution to real-world discovery programs.

Our Team

Image

Handol Kim

Image

Jason Rolfe, PhD

Image

Ali Saberali, PhD

Image

Peter Guzzo, PhD

Image

Roslynn Drewitt-Lange

Image

Ahmad Issa, PhD

Image

Marshall Drew-Brook

Image

Sara Ibrahim Omar, PhD

Image

Alex Perryman, PhD

Image

Brian Atwood, PhD

Image

Matthew Quenneville, PhD

Image

James McSally, PhD

Image

Yizhou Zhang, PhD

Image

Jérôme Rony, PhD

Image

Valentin Beuchillot

Image

Sumin Park

Image

Mahdi Gilany, PhD

Boards of Directors

Image

Frank Chang

Image

Handol Kim

Image

Hanqing Li

Image

Jason Robertson

Image

Jason Rolfe, PhD

Scientific Advisory Board

Image

John Boylan, PhD

Image

Artem Cherkasov, PhD

Image

Alexander Tropsha, PhD

Image

Robert N. Young, PhD

Advisors

Image

Jennifer Hamilton, PhD

Image

Nancy Harrison

Image

Todd Farrell

Variational AI is backed by top-tier investors in healthcare, life sciences, and artificial intelligence.

Our investors include: Nimbus Synergies, Merck Global Health Innovation Fund, Flying Fish Ventures, A&E Investments, Nepenthe Capital, and an alliance of Angel investors. This support fuels the continued development of our generative AI platform, Enki, and strengthens our ability to collaborate with biopharma partners across therapeutic areas.

Image
Image
Image
Image
Image
Image
Image
Image

Looking to contact us? Reach out for more information